|
1
|
Cai S, Zhang T, Zhang D, Qiu G and Liu Y:
Volume-sensitive chloride channels are involved in cisplatin
treatment of osteosarcoma. Mol Med Rep. 11:2465–2470. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Y, Zhang L, Zhang G, Li S, Duan J,
Cheng J, Ding G, Zhou C, Zhang J, Luo P, et al: Osteosarcoma
metastasis: Prospective role of ezrin. Tumor Biol. 35:5055–5059.
2014. View Article : Google Scholar
|
|
3
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang Y and Teng JS: Increased multi-drug
resistance and reduced apoptosis in osteosarcoma side population
cells are crucial factors for tumor recurrence. Exp Ther Med.
12:81–86. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang X, Zheng H, Shou T, Tang C, Miao K
and Wang P: Effectiveness of multi-drug regimen chemotherapy
treatment in osteosarcoma patients: A network meta-analysis of
randomized controlled trials. J Orthop Surg Res. 12:522017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hattinger CM, Pasello M, Ferrari S, Picci
P and Serra M: Emerging drugs for high-grade osteosarcoma. Expert
Opin Emerg Drugs. 15:615–634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chou AJ and Gorlick R: Chemotherapy
resistance in osteosarcoma: Current challenges and future
directions. Expert Rev Anticancer Ther. 6:1075–1085. 2016.
View Article : Google Scholar
|
|
8
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brasseur K, Gévry N and Asselin E:
Chemoresistance and targeted therapies in ovarian and endometrial
cancers. Oncotarget. 8:4008–4042. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu C and Shervington A: Chemoresistance in
gliomas. Mol Cell Biochem. 312:71–80. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang JZ, Ma SR, Rong XL, Zhu MJ, Ji QY,
Meng LJ, Gao YY, Yang YD and Wang Y: Characterization of
multidrug-resistant osteosarcoma sublines and the molecular
mechanisms of resistance. Mol Med Rep. 14:3269–3276. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Felciano RM, Bavari S, Richards DR,
Billaud JN, Warren T, Panchal R and Krämer A: Predictive systems
biology approach to broad-spectrum, host-directed drug target
discovery in infectious diseases. Pac Symp Biocomput. 17–28.
2013.PubMed/NCBI
|
|
13
|
Calvano SE, Xiao W, Richards DR, Felciano
RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK,
et al: A network-based analysis of systemic inflammation in humans.
Nature. 437:1032–1037. 2013. View Article : Google Scholar
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Z, Xia Q, Cui J, Diao Y and Li J:
Reversion of P-glycoprotein-mediated multidrug resistance by
diallyl trisulfide in a human osteosarcoma cell line. Oncol Rep.
31:2720–2726. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tahara T, Arisawa T, Shibata T, Hirata I
and Nakano H: Multi-drug resistance 1 polymorphism is associated
with reduced risk of gastric cancer in the Japanese population. J
Gastroenterol Hepatol. 22:1678–1682. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhou R, Huang W, Yao Y, Wang Y, Li Z, Shao
B, Zhong J, Tang M, Liang S, Zhao X, et al: CA II, a potential
biomarker by proteomic analysis, exerts significant inhibitory
effect on the growth of colorectal cancer cells. Int J Oncol.
43:611–621. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Faye MD, Beug ST, Graber TE, Earl N, Xiang
X, Wild B, Langlois S, Michaud J, Cowan KN, Korneluk RG and Holcik
M: IGF2BP1 controls cell death and drug resistance in
rhabdomyosarcomas by regulating translation of cIAP1. Oncogene.
34:1532–1541. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xie XQ, Zhao QH, Wang H and Gu KS:
Dysregulation of mRNA profile in cisplatin-resistant gastric cancer
cell line SGC7901. World J Gastroentero. 23:1189–1202. 2017.
View Article : Google Scholar
|
|
20
|
Chiang YC, Lin HW, Chang CF, Chang MC, Fu
CF, Chen TC, Hsieh SF, Chen CA and Cheng WF: Overexpression of
CHI3L1 is associated with chemoresistance and poor outcome of
epithelial ovarian carcinoma. Oncotarget. 6:39740–39755. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Januchowski R, Świerczewska M, Sterzyńska
K, Wojtowicz K, Nowicki M and Zabel M: Increased expression of
several collagen genes is associated with drug resistance in
ovarian cancer cell lines. J Cancer. 7:1295–1310. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yuan J, Yin Z, Tao K, Wang G and Gao J:
Function of insulin-like growth factor 1 receptor in cancer
resistance to chemotherapy. Oncol Lett. 15:41–47. 2018.PubMed/NCBI
|
|
23
|
Spaargaren M, Beuling EA, Rurup ML, Meijer
HP, Klok MD, Middendorp S, Hendriks RW and Pals ST: The B cell
antigen receptor controls integrin activity through Btk and
PLCgamma2. J Exp Med. 198:1539–1550. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu W, Barnette AR, Andreansky S and
Landgraf R: ERBB2 overexpression establishes ERBB3-dependent
hypersensitivity of breast cancer cells to withaferin A. Mol Cancer
Ther. 15:2750–2757. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ekstrand AJ, James CD, Cavenee WK, Seliger
B, Pettersson RF and Collins VP: Genes for epidermal growth factor
receptor, transforming growth factor, and epidermal growth factor
and their expression in human gliomas in vivo. Cancer Res.
51:2164–2172. 1991.PubMed/NCBI
|
|
26
|
Suh KJ, Sung JH, Kim JW, Han SH, Lee HS,
Min A, Kang MH, Kim JE, Kim JW, Kim SH, et al: EGFR or HER2
inhibition modulates the tumor microenvironment by suppression of
PD-L1 and cytokines release. Oncotarget. 8:63901–63910. 2017.
View Article : Google Scholar : PubMed/NCBI
|
